Lilly

Former Lilly neuroscience chief heads to J&J

Tuesday, March 8, 2011 11:08 AM

Former Eli Lilly neuroscience chief David Bredt’s recent resignation was not due to the company's setbacks in that field, according to FierceBiotech. Bredt has landed a new job in the neuroscience research group at Johnson & Johnson, which is looking to advance its own pipeline of drugs for Alzheimer's and other neurological diseases.

More... »

Eli Lilly neuroscience chief steps down

Tuesday, March 1, 2011 08:52 AM

Faced with several clinical setbacks, Eli Lilly neuroscience chief David Bredt has left the company. Bredt joined Lilly in 2004, according to the Wall Street Journal.

More... »

ProPublica report: big pharma paid hundreds of physicians over $100,000 in speaking fees

Monday, November 8, 2010 11:12 AM

Several doctors paid to speak on behalf of big pharmaceutical companies aren’t, in fact, the thought leaders consumers often consider them to be, but instead have been sanctioned for various forms of misconduct. And psychiatrists collect more in speaking and consulting fees from pharma companies than doctors in any other specialty.

More... »

Site Solutions Summit honors Eli Lilly, PPD with Eagle Awards

Wednesday, October 20, 2010 02:19 PM

The complexity of today’s clinical trials, the regulatory burdens and the disease states being tackled make the current drug discovery market a difficult one in which to operate, Dr. Jeffrey Kasher, vice president of clinical development organization for Lilly Research Laboratories at Eli Lilly, told more than 350 industry members last Saturday evening at the Site Solutions Summit in Clearwater Beach, Fla.

More... »

More big pharmaceuticals join trend of partnering with CROs to cut costs, speed drug development

Monday, October 11, 2010 10:27 AM

Major pharmaceutical companies are increasingly forming long-term, strategic partnerships with a small number of global contract research organizations (CROs) in order to cut costs and streamline their outsourced clinical work.

More... »

Eli Lilly expands its outsourcing partnership with i3 Statprobe

Tuesday, September 28, 2010 07:40 AM

Expanding the outsourcing support of its clinical trials, Eli Lilly is transferring U.S. medical writing and biostatistical services to i3 Statprobe, a move that expands the business relationship formed between the two companies in 2008 when Lilly transferred the majority of its domestic data management activities to i3.

More... »

PPD Names CIO and EVP for Global Clinical Development

Monday, June 21, 2010 09:45 AM

Contract research organization PPD appointed Mike Wilkinson, Ph.D., as executive vice president and chief information officer and Paul Colvin as executive vice president of global clinical development.

More... »

Covance Launches Discovery and Translational Services Division

Monday, May 17, 2010 12:59 PM

Covance has reorganized its early-stage drug development work into a new division dedicated to discovery services, antibody products and immunology. The new group, Discovery and Translational Services, integrates the CRO’s Biomarker Center for Excellence, formed in 2009, with its Genomics Laboratory and existing partnerships with Caprion Proteomics and Rules-Based Medicine. 

More... »

Covance to Close Preclinical Site

Tuesday, April 20, 2010 06:41 AM

Covance is closing a testing site in Kalamazoo, Mich., as part of the CRO’s ongoing efforts to cut back its preclinical services. The site will be closed by November, and, according to published reports, 63 workers will lose their jobs.

More... »

Covance-Lilly Deal Continues to Bloom

Monday, March 15, 2010 06:51 AM

A little more than a year after Covance entered into a ground-breaking $1.6-billion drug development agreement with Eli Lilly, the contract research organization (CRO) continues to reap the awards of that deal and recently expanded the relationship.

More... »